Patents Examined by Benjamin Packard
  • Patent number: 10111810
    Abstract: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: October 30, 2018
    Assignee: Aquestive Therapeutics, Inc.
    Inventors: Robert K. Yang, Richard C. Fuisz, Garry L. Myers, Joseph M. Fuisz
  • Patent number: 10085442
    Abstract: The present invention relates to a composition comprising an aqueous continuous phase; a first dispersed phase which comprises styrene-maleimide copolymer particles; and a second dispersed phase which is either oil droplets, suspended particles or a capsule suspension; and to use of those compositions to control agricultural pests or diseases. It also relates to use of such compositions where rainfastness is important.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: October 2, 2018
    Inventors: John Henry Nettleton-Hammond, Niall Rae Thomson, Dirk Armand Wim Stanssens
  • Patent number: 10077232
    Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: September 18, 2018
    Inventors: James Heyes, Mark Wood, Alan Martin
  • Patent number: 10064863
    Abstract: Pharmaceutical compositions and single unit dosage forms of Compound A (3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione), or an enantiomer or a mixture of enantiomers thereof, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, are provided herein. Also provided are methods of treating, managing, or preventing cancer using the dosage forms described herein.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: September 4, 2018
    Assignee: Celgene Corporation
    Inventors: Colin Walters, William Bowen, Yali Sun, Jay Brumfield, Xiaoxuan Shen, Daozhong Zou, Indrajit Ghosh
  • Patent number: 10052400
    Abstract: The present invention relates to a method for preparing a neutralized matrix of non-antigenic collagenous material comprising the steps of: —a) preparing an acidic solution of non-antigenic collagenous material, —b) pouring the solution of a) into a mold in order to form a layer, —c) lyophilizing the layer of b) in order to obtain an acidic matrix of non-antigenic collagenous material, d) sterilizing the acidic matrix obtained in c) with ethylene oxide in order to obtain a neutralized matrix of non-antigenic collagenous material. The invention also relates to the matrices obtained and to surgical implants comprising such matrices.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 21, 2018
    Assignee: Sofradim Production
    Inventors: Amandine Jaillon, Aurelie Serrero
  • Patent number: 10052387
    Abstract: Based on the observation that the application of small amounts of exogenous acid sphingomyelinase to generate endogenous ceramide, or provision of exogenous long-chain natural C16-ceramide resulted in rapid translocation of vacuolar daunorubicin into the nucleus in multi-drug resistant (MDR) cells, the present invention relates to a nano-liposomal preparation that includes C16-ceramide. Exposure of MDR cells to the C16:0 ceramide-based nanoliposomes provide a mechanism to reverse MDR in chemoresistant cells and tumors, by inducing rapid translocation of chemotherapeutic agent from cytoplasmic vesicles to the nucleus.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 21, 2018
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, Yissum Research Development Company of the Hebrew University LTD
    Inventors: Richard Kolesnick, Yechezkel Barenholz, Erez Koren
  • Patent number: 10053520
    Abstract: The disclosure provides coated mammalian cells, and related reagents, as well as methods for coating mammalian cells, and methods for implanting the coated cells into a human host.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: August 21, 2018
    Inventors: David W. Scharp, Alexander Gorkovenko
  • Patent number: 10052045
    Abstract: The present invention relates to a method for testing oral malodor, in particular oral malodor from onion and garlic. Described herein are methods for testing the efficacy of an oral care composition to reduce oral malodor, the method comprising the steps of: a) cleaning at least a part of the oral cavity with an oral care composition; b) testing a first sample of exhaled breath from the cleaned oral cavity to provide a first test result representing a first amount of at least one oral malodor component detected in the exhaled breath; c) exposing the oral cavity to an oral malodor material including or capable of forming the at least one oral malodor component; and d) testing a second sample of exhaled breath from the oral cavity to provide a second test result representing a second amount of the at least one oral malodor component detected in the exhaled breath.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 21, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Zhigang Hao, Deborah A. Peru, Joe Vazquez, Jessica Monk, Harsh M. Trivedi, Paul Joseph Vincenti, Osman Khalid
  • Patent number: 10045950
    Abstract: Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C?C—, (a tolan), —CH?CH— (a stilbene, preferably trans); or —CRa?CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3?, 4, 4?, and/or 5, 5?; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ?1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: August 14, 2018
    Assignee: BIOMENDICS, LLC
    Inventors: Chun-che Tsai, Karen M. McGuire, James M. Jamison, Jack L. Summers
  • Patent number: 10045946
    Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: August 14, 2018
    Inventor: Gopi M. Venkatesh
  • Patent number: 10034832
    Abstract: Technologies are described for formulations and methods to produce sublingual antidepressant lozenges. The lozenges may comprise troche base and ketamine. The lozenges may comprise 0.35 weight percent to 0.65 weight percent ketamine. The methods may comprise placing troche base into a chamber. The methods may comprise applying heat to the chamber. The heat may be sufficient to melt the troche base in the chamber. The methods may comprise adding a first ingredient into the chamber. The first ingredient may include ketamine. The methods may comprise mixing the first ingredient into the melted troche base in the chamber to form a melted mixture. The methods may comprise pouring the melted mixture into a mold. The methods may comprise cooling the melted mixture in the mold to form the lozenge.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: July 31, 2018
    Assignee: Synergistic Therapeutics, LLC
    Inventors: Anthony H. Salce, Jr., William F. Greenwood, Shivsankar Misir
  • Patent number: 10034887
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: July 31, 2018
    Assignee: M.G. THERAPEUTICS, LTD.
    Inventors: Yair Alster, Omer Rafaeli, K. Angela MacFarlane, Cary Reich, Shimon Amselem, Doron Friedman
  • Patent number: 10028994
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 24, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10022338
    Abstract: This disclosure describes compounds that affect the olfactory responses of the honey bee mite (Varroa destructor) and methods of use thereof. The compounds do not kill Varroa destructor, and are therefore unlikely to generate Varroa destructor resistance, compared to an acaricide. The compounds can work in conjunction with other mite control approaches, such as a bottom board excluder and sticky board control devices, and can enhance the performance of other forms of mite control while decreasing disadvantages associated therewith.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: July 17, 2018
    Assignees: Simon Fraser University, The State of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center)
    Inventors: Erika Plettner, Victoria Soroker
  • Patent number: 10016502
    Abstract: An object of the present invention is to provide a patch preparation having an excellent skin permeability of medicament using an acid additional salt of basic medicament. Provided is a patch preparation comprising a support and an adhesive layer on one surface of the support, wherein the adhesive layer contains a basic medicament, a fatty acid-based ionic liquid, and potassium salts and/or potassium ions. Said potassium salts and/or potassium ions are generated as a result of reaction of an acid addition salt of the basic medicament with a compound capable of generating potassium ion in the adhesive layer.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 10, 2018
    Assignee: MEDRx Co., LTD
    Inventors: Hidetoshi Hamamoto, Takahiro Tanimoto
  • Patent number: 9993443
    Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogs, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: June 12, 2018
    Assignee: PhilEra New Zealand Limited
    Inventor: Garth James Smith Cooper
  • Patent number: 9993447
    Abstract: Formulations of hydrosoluble stable organic salts including, but not limited to, agmatine orotate, agmatine di-hydrochloride, agmatine phosphate, buffered agmatine or spray dried buffered agmatine base, whether alone or in combination with one another, are provided, as well as methods for making same. These agmatine salts may have improved solubility in aqueous and organic media and may have increased absorbability and/or tissue bioavailability in humans and animals when compared to agmatine sulfate. These formulations may be administered as a means for improving athletic performance, training resistance and/or cognitive function. These formulations also may increase cellular uptake of agmatine in an animal or human.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: June 12, 2018
    Assignee: JW Nutritional, LLC
    Inventors: Dragos Alevizache, Jesse Windrix
  • Patent number: 9993474
    Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 12, 2018
    Assignee: VeroScience LLC
    Inventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
  • Patent number: 9980906
    Abstract: The present invention provides a slow and controlled released liposomal gel composition for subcutaneous administration comprises insulin or exenatide as active ingredient for reduction of blood sugar level and method of preparation thereof. Said controlled released composition has high bioavailability and is demonstrated to be able to sustain release therapeutically effective concentration of drug over a period of time and without rapid release of drug after initial administration. Method of preparing the controlled released composition of the present invention comprises the following steps: mixing insulin or exenatide, lipid and aqueous dispersion medium together; then mixing with poloxamer (e.g. F127 or P123) and/or gelatin and hyaluronic acid (HA) or the like gel solution so as to form a protective layer on surface of every lipid micro vesicles or nano-vesicles for use in intramuscular, abdominal and subcutaneous administration.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 29, 2018
    Assignee: Hong Kong Baptist University
    Inventors: Zhijun Yang, Aiping Lu, Zhaoxiang Bian, Xiaoyu Chen, Blenda Chi Kwan Wong
  • Patent number: 9980902
    Abstract: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: May 29, 2018
    Assignee: Sigmoid Pharma Limited
    Inventors: Ivan Coulter, Vincenzo Aversa